EKF Diagnostics Holdings plc Logo

EKF Diagnostics Holdings plc

EKF.L

(0.8)
Stock Price

28,05 GBp

-17.25% ROA

-18.43% ROE

-15.66x PER

Market Cap.

142.701.134,00 GBp

2.11% DER

3.66% Yield

-22.61% NPM

EKF Diagnostics Holdings plc Stock Analysis

EKF Diagnostics Holdings plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

EKF Diagnostics Holdings plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (2%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.75x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 ROE

The stock's ROE indicates a negative return (-11.44%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-17.25%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-2), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

EKF Diagnostics Holdings plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

EKF Diagnostics Holdings plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

EKF Diagnostics Holdings plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

EKF Diagnostics Holdings plc Revenue
Year Revenue Growth
2001 1.096.000
2002 1.616.000 32.18%
2003 1.275.000 -26.75%
2004 2.235.000 42.95%
2005 3.261.000 31.46%
2006 3.077.000 -5.98%
2007 341.000 -802.35%
2008 465.000 26.67%
2009 0 0%
2010 6.483.000 100%
2011 21.658.000 70.07%
2012 26.060.000 16.89%
2013 31.804.000 18.06%
2014 40.062.000 20.61%
2015 30.045.000 -33.34%
2016 38.589.000 22.14%
2017 41.584.000 7.2%
2018 42.543.000 2.25%
2019 44.917.000 5.29%
2020 65.260.000 31.17%
2021 81.836.000 20.26%
2022 66.635.000 -22.81%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

EKF Diagnostics Holdings plc Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 143.000 100%
2011 269.000 46.84%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

EKF Diagnostics Holdings plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 626.000
2002 1.187.000 47.26%
2003 1.322.000 10.21%
2004 1.963.000 32.65%
2005 1.402.000 -40.01%
2006 894.000 -56.82%
2007 0 0%
2008 30.000 100%
2009 386.000 92.23%
2010 2.386.000 83.82%
2011 9.298.000 74.34%
2012 14.651.000 36.54%
2013 14.439.000 -1.47%
2014 22.793.000 36.65%
2015 29.156.000 21.82%
2016 18.734.000 -55.63%
2017 18.186.000 -3.01%
2018 10.586.000 -71.79%
2019 18.280.000 42.09%
2020 20.658.000 11.51%
2021 17.709.000 -16.65%
2022 23.177.000 23.59%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

EKF Diagnostics Holdings plc EBITDA
Year EBITDA Growth
2001 -619.000
2002 -1.180.000 47.54%
2003 -1.529.000 22.83%
2004 -1.963.000 22.11%
2005 -39.000 -4933.33%
2006 -741.000 94.74%
2007 181.000 509.39%
2008 -2.403.000 107.53%
2009 -873.000 -175.26%
2010 -6.836.000 87.23%
2011 -10.894.000 37.25%
2012 3.027.000 459.89%
2013 5.275.000 42.62%
2014 744.000 -609.01%
2015 -7.743.000 109.61%
2016 4.671.000 265.77%
2017 9.405.000 50.33%
2018 16.233.000 42.06%
2019 9.763.000 -66.27%
2020 21.559.000 54.71%
2021 27.677.000 22.1%
2022 8.569.000 -222.99%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

EKF Diagnostics Holdings plc Gross Profit
Year Gross Profit Growth
2001 1.096.000
2002 1.616.000 32.18%
2003 1.099.000 -47.04%
2004 1.674.000 34.35%
2005 1.975.000 15.24%
2006 1.574.000 -25.48%
2007 341.000 -361.58%
2008 465.000 26.67%
2009 0 0%
2010 2.911.000 100%
2011 10.381.000 71.96%
2012 14.313.000 27.47%
2013 16.345.000 12.43%
2014 19.949.000 18.07%
2015 14.669.000 -35.99%
2016 18.322.000 19.94%
2017 22.863.000 19.86%
2018 22.696.000 -0.74%
2019 23.727.000 4.35%
2020 37.420.000 36.59%
2021 39.366.000 4.94%
2022 24.038.000 -63.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

EKF Diagnostics Holdings plc Net Profit
Year Net Profit Growth
2001 294.000
2002 143.000 -105.59%
2003 -475.000 130.11%
2004 -589.000 19.35%
2005 773.000 176.2%
2006 596.000 -29.7%
2007 465.000 -28.17%
2008 -1.307.000 135.58%
2009 -203.000 -543.84%
2010 -3.435.000 94.09%
2011 -2.884.000 -19.11%
2012 1.830.000 257.6%
2013 -1.126.000 262.52%
2014 -5.689.000 80.21%
2015 -37.123.000 84.68%
2016 -18.000 -206138.89%
2017 2.715.000 100.66%
2018 10.110.000 73.15%
2019 3.932.000 -157.12%
2020 11.114.000 64.62%
2021 15.851.000 29.88%
2022 -9.576.000 265.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

EKF Diagnostics Holdings plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

EKF Diagnostics Holdings plc Free Cashflow
Year Free Cashflow Growth
2001 -97.000
2002 -96.000 -1.04%
2003 -38.000 -152.63%
2004 -934.000 95.93%
2005 -17.000 -5394.12%
2006 -1.276.000 98.67%
2007 577.000 321.14%
2008 -647.000 189.18%
2009 -676.000 4.29%
2010 -3.887.000 82.61%
2011 -3.021.000 -28.67%
2012 -339.000 -791.15%
2013 -275.000 -23.27%
2014 -7.377.000 96.27%
2015 -9.677.000 23.77%
2016 7.019.000 237.87%
2017 6.840.000 -2.62%
2018 6.471.000 -5.7%
2019 681.250 -849.87%
2020 11.164.000 93.9%
2021 4.589.000 -143.28%
2022 3.860.000 -18.89%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

EKF Diagnostics Holdings plc Operating Cashflow
Year Operating Cashflow Growth
2001 142.000
2002 8.000 -1675%
2003 -27.000 129.63%
2004 -852.000 96.83%
2005 20.000 4360%
2006 -826.000 102.42%
2007 577.000 243.15%
2008 -647.000 189.18%
2009 -676.000 4.29%
2010 -1.409.000 52.02%
2011 -806.000 -74.81%
2012 1.599.000 150.41%
2013 2.007.000 20.33%
2014 -4.744.000 142.31%
2015 -4.285.000 -10.71%
2016 8.943.000 147.91%
2017 9.053.000 1.22%
2018 8.323.000 -8.77%
2019 1.275.000 -552.78%
2020 13.809.000 90.77%
2021 10.238.000 -34.88%
2022 9.688.000 -5.68%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

EKF Diagnostics Holdings plc Capital Expenditure
Year Capital Expenditure Growth
2001 239.000
2002 104.000 -129.81%
2003 11.000 -845.45%
2004 82.000 86.59%
2005 37.000 -121.62%
2006 450.000 91.78%
2007 0 0%
2008 0 0%
2009 0 0%
2010 2.478.000 100%
2011 2.215.000 -11.87%
2012 1.938.000 -14.29%
2013 2.282.000 15.07%
2014 2.633.000 13.33%
2015 5.392.000 51.17%
2016 1.924.000 -180.25%
2017 2.213.000 13.06%
2018 1.852.000 -19.49%
2019 593.750 -211.92%
2020 2.645.000 77.55%
2021 5.649.000 53.18%
2022 5.828.000 3.07%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

EKF Diagnostics Holdings plc Equity
Year Equity Growth
2001 214.000
2002 2.902.000 92.63%
2003 2.458.000 -18.06%
2004 3.115.000 21.09%
2005 3.714.000 16.13%
2006 4.299.000 13.61%
2007 4.976.000 13.61%
2008 5.070.000 1.85%
2009 5.620.000 9.79%
2010 23.224.000 75.8%
2011 37.041.000 37.3%
2012 38.946.000 4.89%
2013 40.414.000 3.63%
2014 87.023.000 53.56%
2015 46.493.000 -87.17%
2016 60.450.000 23.09%
2017 59.970.000 -0.8%
2018 63.904.000 6.16%
2019 71.172.000 10.21%
2020 78.200.000 8.99%
2021 94.742.000 17.46%
2022 74.523.000 -27.13%
2023 65.266.000 -14.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

EKF Diagnostics Holdings plc Assets
Year Assets Growth
2001 5.448.000
2002 6.432.000 15.3%
2003 6.326.000 -1.68%
2004 6.657.000 4.97%
2005 4.843.000 -37.46%
2006 5.161.000 6.16%
2007 5.565.000 7.26%
2008 5.738.000 3.01%
2009 6.397.000 10.3%
2010 35.979.000 82.22%
2011 58.733.000 38.74%
2012 55.717.000 -5.41%
2013 60.723.000 8.24%
2014 135.779.000 55.28%
2015 71.889.000 -88.87%
2016 82.432.000 12.79%
2017 77.157.000 -6.84%
2018 81.380.000 5.19%
2019 87.126.000 6.6%
2020 101.265.000 13.96%
2021 115.119.000 12.03%
2022 89.291.000 -28.93%
2023 82.251.000 -8.56%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

EKF Diagnostics Holdings plc Liabilities
Year Liabilities Growth
2001 5.234.000
2002 3.530.000 -48.27%
2003 3.868.000 8.74%
2004 3.542.000 -9.2%
2005 1.129.000 -213.73%
2006 862.000 -30.97%
2007 589.000 -46.35%
2008 668.000 11.83%
2009 777.000 14.03%
2010 12.450.000 93.76%
2011 21.306.000 41.57%
2012 16.290.000 -30.79%
2013 19.801.000 17.73%
2014 48.403.000 59.09%
2015 25.135.000 -92.57%
2016 21.461.000 -17.12%
2017 16.659.000 -28.83%
2018 17.476.000 4.67%
2019 15.954.000 -9.54%
2020 23.065.000 30.83%
2021 20.377.000 -13.19%
2022 14.768.000 -37.98%
2023 16.985.000 13.05%

EKF Diagnostics Holdings plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.15
Net Income per Share
-0.02
Price to Earning Ratio
-15.66x
Price To Sales Ratio
2.14x
POCF Ratio
15.48
PFCF Ratio
36.97
Price to Book Ratio
2.04
EV to Sales
1.99
EV Over EBITDA
15.48
EV to Operating CashFlow
13.69
EV to FreeCashFlow
34.37
Earnings Yield
-0.06
FreeCashFlow Yield
0.03
Market Cap
0,14 Bil.
Enterprise Value
0,13 Bil.
Graham Number
0.27
Graham NetNet
0.02

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
-1.08
ROE
-0.11
Return On Assets
-0.15
Return On Capital Employed
0.06
Net Income per EBT
0.97
EBT Per Ebit
-3.49
Ebit per Revenue
0.07
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0.35
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
-0
Gross Profit Margin
0.45
Operating Profit Margin
0.07
Pretax Profit Margin
-0.23
Net Profit Margin
-0.23

Dividends

Dividend Yield
0.04
Dividend Yield %
3.66
Payout Ratio
-0.57
Dividend Per Share
0.01

Operating Metrics

Operating Cashflow per Share
0.02
Free CashFlow per Share
0.01
Capex to Operating CashFlow
-0.6
Capex to Revenue
-0.09
Capex to Depreciation
-0.88
Return on Invested Capital
0.03
Return on Tangible Assets
-0.17
Days Sales Outstanding
58.93
Days Payables Outstanding
71.02
Days of Inventory on Hand
80.84
Receivables Turnover
6.19
Payables Turnover
5.14
Inventory Turnover
4.52
Capex per Share
-0.01

Balance Sheet

Cash per Share
0,03
Book Value per Share
0,16
Tangible Book Value per Share
0.09
Shareholders Equity per Share
0.16
Interest Debt per Share
0
Debt to Equity
0.02
Debt to Assets
0.02
Net Debt to EBITDA
-1.17
Current Ratio
2.71
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.02
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.38
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
11336000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

EKF Diagnostics Holdings plc Dividends
Year Dividends Growth
2020 1
2021 1 0%
2022 1 0%
2023 0 0%

EKF Diagnostics Holdings plc Profile

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

CEO
Mr. Andrew Webb
Employee
356
Address
Avon House
Cardiff, CF64 2EZ

EKF Diagnostics Holdings plc Executives & BODs

EKF Diagnostics Holdings plc Executives & BODs
# Name Age
1 Mr. Julian Huw Baines M.B.E.
Executive Chairman
70
2 Mr. Stephen Young A.C.M.A.
Chief Financial Officer & Director
70
3 Mr. Andrew Webb
Chief Executive Officer of Ekf Molecular
70

EKF Diagnostics Holdings plc Competitors